📊 CLPT Key Takeaways
Is ClearPoint Neuro, Inc. (CLPT) a Good Investment?
ClearPoint Neuro is burning cash operationally while maintaining stagnant revenue with zero YoY growth, indicating fundamental business challenges beyond typical medtech development cycles. The company carries unsustainable debt (2.63x leverage) relative to equity while unable to cover interest from operations, leaving it dependent on cash reserves that will deplete in 4+ years at current burn rates. Without evidence of revenue acceleration, path to profitability, or positive cash flow generation, the current financial structure is deteriorating shareholder value.
ClearPoint Neuro shows decent product-level economics with a 61.4% gross margin, but those economics are being overwhelmed by operating costs, producing deeply negative operating and net margins on flat revenue. Financial health is mixed: liquidity is strong with $45.92M of cash and a 5.91x current ratio, but leverage is meaningful at 1.75x debt/equity and cash burn remains heavy. Until revenue growth reaccelerates and losses narrow materially, the fundamentals look weak rather than durable.
ClearPoint Neuro, Inc. Key Strengths (CLPT)
- Gross margin of 64% demonstrates products have underlying pricing power and cost structure
- Strong short-term liquidity with current ratio of 5.79x provides operational runway
- Cash position of $35.6M provides 4+ years of runway at current burn rates
- Strong liquidity position with $45.92M in cash and high current and quick ratios
- Healthy gross margin suggests the core products have solid underlying unit economics
- Asset base remains supported by positive equity despite ongoing losses
CLPT Stock Risks: ClearPoint Neuro, Inc. Investment Risks
- Zero revenue growth (0% YoY) suggests failed commercialization or market acceptance issues despite cash investment
- Operating cash flow negative at -$8.0M; company cannot sustain itself from core business
- Debt/Equity of 2.63x with -104.7x interest coverage ratio signals insolvency risk if cash depletes
- Profitability deteriorating with diluted EPS declining 28.6% YoY
- Free cash flow deeply negative at -$8.6M (-71% FCF margin) with no profitability to offset losses
- Flat revenue combined with very large operating losses indicates poor operating leverage
- Negative operating cash flow and free cash flow suggest continued dependence on external capital or balance-sheet resources
- High debt relative to equity and negative interest coverage increase financial risk if losses persist
Key Metrics to Watch
- Revenue growth rate acceleration above zero to demonstrate market traction
- Operating cash flow return to positive territory and path to cash breakeven
- Operating margin improvement toward breakeven as prerequisite for viability
- Debt reduction strategy and timeline given current leverage unsustainability
- Revenue growth relative to operating expense growth
- Operating cash burn and free cash flow trend
ClearPoint Neuro, Inc. (CLPT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.79x current ratio provides a solid financial cushion.
CLPT Profit Margin, ROE & Profitability Analysis
CLPT vs Healthcare Sector: How ClearPoint Neuro, Inc. Compares
How ClearPoint Neuro, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ClearPoint Neuro, Inc. Stock Overvalued? CLPT Valuation Analysis 2026
Based on fundamental analysis, ClearPoint Neuro, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ClearPoint Neuro, Inc. Balance Sheet: CLPT Debt, Cash & Liquidity
CLPT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: ClearPoint Neuro, Inc.'s revenue has grown significantly by 54% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.70 indicates the company is currently unprofitable.
CLPT Revenue Growth, EPS Growth & YoY Performance
CLPT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $8.5M | -$6.0M | $-0.22 |
| Q3 2025 | $8.1M | -$4.1M | $-0.18 |
| Q2 2025 | $7.9M | -$4.1M | $-0.16 |
| Q1 2025 | $7.6M | -$4.1M | $-0.16 |
| Q3 2024 | $5.8M | -$4.1M | $-0.18 |
| Q2 2024 | $6.0M | -$4.1M | $-0.16 |
| Q1 2024 | $5.4M | -$4.1M | $-0.16 |
| Q3 2023 | $5.1M | -$3.8M | $-0.15 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ClearPoint Neuro, Inc. Dividends, Buybacks & Capital Allocation
CLPT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for ClearPoint Neuro, Inc. (CIK: 0001285550)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CLPT
What is the AI rating for CLPT?
ClearPoint Neuro, Inc. (CLPT) has a Combined AI Grade of C from Claude (D) and ChatGPT (C) with 87% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CLPT's key strengths?
Claude: Gross margin of 64% demonstrates products have underlying pricing power and cost structure. Strong short-term liquidity with current ratio of 5.79x provides operational runway. ChatGPT: Strong liquidity position with $45.92M in cash and high current and quick ratios. Healthy gross margin suggests the core products have solid underlying unit economics.
What are the risks of investing in CLPT?
Claude: Zero revenue growth (0% YoY) suggests failed commercialization or market acceptance issues despite cash investment. Operating cash flow negative at -$8.0M; company cannot sustain itself from core business. ChatGPT: Flat revenue combined with very large operating losses indicates poor operating leverage. Negative operating cash flow and free cash flow suggest continued dependence on external capital or balance-sheet resources.
What is CLPT's revenue and growth?
ClearPoint Neuro, Inc. reported revenue of $12.1M.
Does CLPT pay dividends?
ClearPoint Neuro, Inc. does not currently pay dividends.
Where can I find CLPT SEC filings?
Official SEC filings for ClearPoint Neuro, Inc. (CIK: 0001285550) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CLPT's EPS?
ClearPoint Neuro, Inc. has a diluted EPS of $-0.32.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CLPT's fundamental grade?
Based on our AI fundamental analysis in June 2026, ClearPoint Neuro, Inc. has a C grade with 87% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CLPT stock overvalued or undervalued?
Valuation metrics for CLPT: ROE of -50.7% (sector avg: 15%), net margin of -78.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CLPT's AI grade for 2026?
Our dual AI analysis gives ClearPoint Neuro, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CLPT's free cash flow?
ClearPoint Neuro, Inc.'s operating cash flow is $-8.0M, with capital expenditures of $645.0K. FCF margin is -71.0%.
How does CLPT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -78.8% (avg: 12%), ROE -50.7% (avg: 15%), current ratio 5.79 (avg: 2).
Is ClearPoint Neuro, Inc. carrying too much debt?
CLPT has a debt-to-equity ratio of 2.63x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 5.79 suggests adequate short-term liquidity.